Anton Warshavsky

Anton Warshavsky

Auto-generated profile, based on publicly available information

Anton Warshavsky

Gray Faculty of Medical and Health Sciences Tel Aviv University Tel Aviv Israel

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 August 2020 in Head & Neck
Verified
Journal Article
Closed access
PDF file
AWAnton Warshavsky
Anton Warshavsky
RRRoni Rosen
Roni Rosen
CPChava Perry
Chava Perry
NMNidal Muhanna
Nidal Muhanna
OUOmer J. Ungar
Omer J. Ungar
GHGilad Horowitz
Gilad Horowitz

11 November 2020 in Annals of Surgical Oncology
Verified
Journal Article
Closed access
PDF file
AWAnton Warshavsky
Anton Warshavsky
RRRoni Rosen
Roni Rosen
NMNidal Muhanna
Nidal Muhanna
OUOmer J. Ungar
Omer J. Ungar
NNNarin Nard-Carmel
Narin Nard-Carmel
GHGilad Horowitz
Gilad Horowitz

21 April 2021 in The Laryngoscope
Verified
Journal Article
Closed access
PDF file
LSLiam Simani
Liam Simani
YOYahav Oron
Yahav Oron
OHOphir Handzel
Ophir Handzel
RERani Abu Eta
Rani Abu Eta
AWAnton Warshavsky
Anton Warshavsky
OUOmer J. Ungar
Omer J. Ungar

1 October 2019 in International Journal of Oral and Maxillofacial Surgery
Verified
Journal Article
Closed access
AWA. Warshavsky
A. Warshavsky
DFD.M. Fliss
D.M. Fliss
GFG. Frenkel
G. Frenkel
AKA. Kupershmidt
A. Kupershmidt
NMN. Moav
N. Moav
GHG. Horowitz
G. Horowitz

30 July 2021 in Clinical Otolaryngology
Verified
Journal Article
Closed access
PDF file
OUOmer J. Ungar
Omer J. Ungar
HBHarel Baris
Harel Baris
YOYahav Oron
Yahav Oron
SSShahaf Shilo
Shahaf Shilo
OHOphir Handzel
Ophir Handzel
Narin Carmel NeidermanNarin Carmel Neiderman
Narin Carmel Neiderman

20 September 2023 in Biomolecules
Verified
Journal Article
Open access
PDF file
LKLiyona Kampel
Liyona Kampel
SFSara Feldstein
Sara Feldstein
STShlomo Tsuriel
Shlomo Tsuriel
VHVictoria Hannes
Victoria Hannes
Narin Carmel NeidermanNarin Carmel Neiderman
Narin Carmel Neiderman
NMNidal Muhanna
Nidal Muhanna
Circulating tumor DNA (ctDNA) has been suggested as a surrogate biomarker for early detection of cancer recurrence. We aimed to explore the utility of ctDNA as a noninvasive prognostic biomarker in newly diagnosed head and neck squamous cell carcinoma (HNSCC) patients. Seventy HNSCC specimens were analysed for the detection of TP53 genetic alterations utilizing next-generation sequencing (NGS). TP53 mutations were revealed in 55 (79%). Upon detection of a significant TP53 mutation, circulating cell-free DNA was scrutinized for the presence of the tumor-specific mutation. ctDNA was identified at a minimal allele frequency of 0.08% in 21 out of 30 processed plasma samples. Detectable ctDNA correlated with regional spread (N stage ≥ 1, p = 0.011) and poorer 5-year progression-free survival (20%, 95% CI 10.9 to 28.9, p = 0.034). The high-risk worst pattern of invasion (WPOI grade 4–5) and deep invasion were frequently found in patients whose ctDNA was detected (p = 0.087 and p = 0.072, respectively). Detecting mutated TP53 ctDNA was associated with poor progression-free survival and regional metastases, indicating its potential role as a prognostic biomarker. However, ctDNA detectability in early-stage disease and the mechanisms modulating its release into the bloodstream must be further elucidated.